Catheter-related thrombosis: Risks, diagnosis, and management

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 9, 2006, Pages 889-901

  Linenberger, Michael L ^a,b,c  

^a Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance ^*

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Anticoagulation; Central venous catheter; Deep vein thrombosis; Pulmonary embolism; Thrombosis

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ASPARAGINASE; BLOOD CLOTTING FACTOR 5 LEIDEN; DALTEPARIN; ENOXAPARIN; ESTROGEN; FIBRINOLYTIC AGENT; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; INTERLEUKIN 2; NADROPARIN; PLACEBO; PROGESTERONE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; WARFARIN;

ANTICOAGULANT THERAPY; ARM BLOOD VESSEL; ARTICLE; CANCER PATIENT; CATHETER INFECTION; CATHETER OCCLUSION; CATHETER REMOVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIAGNOSTIC IMAGING; ECHOGRAPHY; HIGH RISK PATIENT; HUMAN; INCIDENCE; LUNG EMBOLISM; PHLEBOGRAPHY; RISK FACTOR; THROMBOGENESIS; THROMBOPHILIA; THROMBOSIS PREVENTION; TREATMENT INDICATION; VEIN OCCLUSION;

EID: 33750078979     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0074     Document Type: Article

References (118)

1. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
2. Joffe HV, Kucher N, Tapson VF, et al. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004;110:1605-1611.
3. Prandoni P, Polistena P, Bernardi E, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157:57-62.
4. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost 2005;3:2471-2478.
5. Giess CS, Thaler H, Bach AM, Hann LE. Clinical experience with upper extremity venous sonography in a high-risk cancer population. J Ultrasound Med 2002;21:1365-1370.
6. Allen AW, Megargell JL, Brown DB, et al. Venous thrombosis associated with the placement of peripherally inserted central catheters. J Vasc Interv Radiol 2000;11:1309-1314.
7. Abdullah BJ, Mohammad N, Sangkar JV, et al. Incidence of upper limb venous thrombosis associated with peripherally inserted central catheters (PICC). Br J Radiol 2005;78:596-600.
8. Grove JR, Pevec WC. Venous thrombosis related to peripherally inserted central catheters. J Vasc Interv Radiol 2000;11:837-840.
9. Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 2002;20:3276-3281.
10. Schwarz RE, Groeger JS, Coit DG. Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer 1997;79:1635-1640.
11. Kuriakose P, Colon-Otero G, Paz-Fumagalli R. Risk of deep venous thrombosis associated with chest versus arm central venous subcutaneous port catheters: a 5-year single-institution retrospective study. J Vasc Interv Radiol 2002;13:179-184.
12. Labourey JL, Lacroix P, Genet D, et al. Thrombotic complications of implanted central venous access devices: prospective evaluation. Bull Cancer 2004;91:431-436.
13. Luciani A, Clement O, Halimi P, et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001;220:655-660.
14. Tesselaar MET, Ouwerkerk J, Nooy MA, et al. Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 2004;40:2253-2259.
15. Puel V, Caudry M, Le Metayer P, et al. Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer 1993;72:2248-2252.
16. Biffi R, De Braud F, Orsi F, et al. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 2001;92:1204-1212.
17. Haire WD, Lieberman RP, Lund GB, et al. Thrombotic complications of silicone rubber catheters during autologous marrow and peripheral stem cell transplantation: prospective comparison of Hickman and Groshong catheters. Bone Marrow Transplant 1991;7:57-59.
18. Haire WD, Lieberman RP, Edney J, et al. Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation. Cancer 1990;66:900-908.
19. Conlan MG, Haire WD, Lieberman RP, et al. Catheter-related thrombosis in patients with refractory lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplant 1991;7:235-240.
20. Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995;13:233-238.
21. Nightingale CE, Norman A, Cunningham D, et al. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Eur J Cancer 1997;33:398-403.
22. Trerotola SO, Kuhn-Fulton J, Johnson MS, et al. Tunneled infusion catheters: increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology 2000;217:89-93.
23. Molinari AC, Castagnola E, Mazzola C, et al. Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters. Support Care Cancer 2001;9:539-544.
24. Fratino G, Molinari AC, Parodi S, et al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Ann Oncol 2005;16:648-654.
25. Horne MK III, May DJ, Alexander HR, et al. Venographic surveillance of tunneled venous access devices in adult oncology patients. Ann Surg Oncol 1995;2:174-178.
26. Barzaghi A, Dell'Oto M, Rovelli A, et al. Central venous catheter clots: incidence, clinical significance and catheter care in patients with hematologic malignanices. Pediatr Hematol Oncol 1995;12:243-250.
27. McLean TW, Fisher CJ, Snively BM, Chauvenet AR. Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement. J Clin Oncol 2005;23:3024-3029.
28. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484-490.
29. Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-a prospective study. Thromb Haemost 1994;72:548-550.
30. Schwarz RE, Coit DG, Groeger JS. Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection. Ann Surg Oncol 2000;7:441-449.
31. Male C, Chait P, Andrew M, et al. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 2003;101:4273-4278.
32. De Cicco M, Matovic M, Balestreri L, et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 1997;86:101-113.
33. Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006;24:1404-1408.
34. Ruesch S, Walder B, Tramer MR. Complications of central venous catheters: internal jugular versus subclavian access-a systematic review. Crit Care Med 2002;30:454-460.
35. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-722.
36. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-464.
37. Haire WD, Lynch TG, Lieberman RP, Edney JA. Duplex scans before subclavian vein catheterization predict unsuccessful catheter placement. Arch Surg 1992;127:229-230.
38. Gupta H, Araki Y, Davidoff AM, et al. Evaluation of pediatric oncology patients with previous multiple central catheters for vascular access: is Doppler ultrasound needed? Pediatr Blood Cancer 2006; Apr 26:Epub ahead of print.
39. Kraybill WG, Allen BT. Preoperative duplex venous imaging in the assessment of patients with venous access. J Surg Oncol 1993;52:244-248.
40. van Rooden CJ, Rosendaal FR, Meinders AE, et al. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004;89:201-206.
41. Cortelezzi A, Moia M, Falanga A, et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005;129:811-817.
42. Lordick F, Hentrich M, Decker T, et al. Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study. Br J Haematol 2003;120:1073-1078.
43. van Rooden CJ, Schippers EF, Barge RMY, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005;23:2655-2660.
44. Miceli M, Atoui R, Walker R, et al. Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report. J Clin Oncol 2004;22:1949-1956.
45. Nowak-Gottl U, Dubbers A, Kececioglu D, et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr 1997;131:608-612.
46. Knofler R, Siegert E, Lauterbach I, et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy-impact of central venous lines. Eur J Pediatr 1999;158(suppl 3): S147-S150.
47. Wermes C, von Depka Prondzinski M, Lichtinghagen R, et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999;158(suppl 3):S143-S146.
48. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93:1595-1599.
49. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 2000;83:840-843.
50. Ruud E, Holmstrom H, Natvig S, Wesenberg F. Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer-a prospective study. Med Pediatr Oncol 2002;38:405-410.
51. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003;97:508-516.
52. Sifontes MT, Nuss R, Hunger SP, et al. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 1997;96:484-489.
53. Riordan M, Weiden PL. Factor V Leiden mutation does not account for central venous catheter-related thrombosis. Am J Hematol 1998;58:150-152.
54. Ratcliffe M, Broadfoot C, Davidson M, et al. Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. Clin Lab Haematol 1999;21:353-357.
55. Ozguroglu M, Arun B, Erzin Y, et al. Serum cardiolipin antibodies in cancer patients with thromboembolic events. Clin Appl Thromb Hemost 1999;5:181-184.
56. Fijnheer R, Paijmans B, Verdonck LF, et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002;118:267-270.
57. Abdelkefi A, Ben Romdhane N, Kriaa A, et al. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients. Bone Marrow Transplant 2005;36:885-889.
58. Jansen FH, van der Straaten HM, Roest M, et al. Elevated levels of D-dimer and fragment 1+2 upon central venous catheter insertion and factor V Leiden predict subclavian vein thrombosis. Haematologica 2005;90:499-504.
59. Mandala M, Curigliano G, Bucciarelli P, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004;15:590-593.
60. Cortelezzia A, Fracchiolla NS, Maisonneuve P, et al. Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures. Leuk Lymphoma 2003;44:1495-1501.
61. Wun T, Law L, Harvey D, et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514-1520.
62. Eastman ME, Khorsand M, Maki DG, et al. Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2. Cancer 2001;91:806-814.
63. Stephens LC, Haite WD, Schmit-Pokorny K, et al. Granulocyte macrophage colony stimulating factor: high incidence of apheresis catheter thrombosis during peripheral stem cell collection. Bone Marrow Transplant 1993;11:51-54.
64. Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 2005;80:1549-1551.
65. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 2004;76:240-244.
66. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003;101:3049-3051.
67. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004;9:207-216.
68. Tolar B, Gould JR. The prognostic significance of the ball-valve effect in Groshong catheters. Support Care Cancer 1996;4:34-38.
69. Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion? J PEN J Patenter Enteral Nutr 1995;19:75-79.
70. Baarslag HJ, Koopman MM, Reekers JA, van Beek EJ. Diagnosis and management of deep vein thrombosis of the upper extremity: a review. Eur Radiol 2004;14:1263-1274.
71. Mustafa BO, Rathbun SW, Whitsett TL, Raskob GE. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med 2002;162:401-404.
72. Baarslag HJ, van Beek EJ, Koopman MM, Reekers JA. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med 2002;136:865-872.
73. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665-3675.
74. van Rooden CJ, Tesselaar ME, Osanto S, et al. Deep vein thrombosis associated with central venous catheters-a review. J Thromb Haemost 2005;3:2409-2419.
75. Baarslag HJ, van Beek EJ, Reekers JA. Magnetic resonance venography in consecutive patients with suspected deep vein thrombosis of the upper extremity: initial experience. Acta Radiol 2004;45:38-43.
76. Minassian VA, Sood AK, Lowe P, et al. Longterm central venous access in gynecologic cancer patients. J Am Coll Surg 2000;191:403-409.
77. Lagro SW, Verdonck LF, Borel Rinkes IH, Dekker AW. No effect of nadropatin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients. Bone Marrow Transplant 2000;26:1103-1106.
78. Magagnoli M, Masci G, Castagna L, et al. Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients. Am J Hematol 2006;81:1-4.
79. Bozzetti F, Scarpa D, Terno G, et al. Subclavian venous thrombosis due to indwelling catheters: a prospective study on 52 patients. JPEN J Patenter Enteral Nutr 1983;7:560-562.
80. Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998;101:483-486.
81. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112:423-428.
82. Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996;75:251-253.
83. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 2002;32:84-88.
84. Mismetti P, Mille D, Laporte S, et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003;88:67-73.
85. Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057-4062.
86. Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063-4069.
87. Karthaus M, Kretzschmar A, Kroning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289-296.
88. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(suppl 1):132S-175S.
89. Carr KM, Rabinowitz I. Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors. J Clin Oncol 2000;18:3665-3667.
90. Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTECT trial. Thromb Res 2003;109:101-108.
91. Geerts W, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithromhotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):338S-400S.
92. Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters-a reappraisal of the evidence. Br J Cancer 2006;94:189-194.
93. Huisman MV. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups. J Thromb Haemost 2006;4:10-13.
94. Agnelli G, Verso M. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? No. J Thromb Haemost 2006;4:14-15.
95. Levine M. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Still an open question. J Thromb Haemost 2006;4:16-18.
96. Abdelkefi A, Ben Othman T, Kammoun L, et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thromb Haemost 2004;92:654-661.
97. Magagnoli M, Masci G, Castagna L, et al. High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens. Ann Oncol 2006;17:174-176.
98. Semba CP, Deitcher SR, Li X, et al. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. J Vasc Interv Radiol 2002;13:1199-1205.
99. Haire WD, Deitcher SR, Mullane KM, et al. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial. Thromb Haemost 2004;92:575-582.
100. Chesler L, Feusner JH. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters. J Pediatr Hematol Oncol 2002;24:653-656.
101. Terrill KR, Lemons RS, Goldsby RE. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer. J Pediatr Hematol Oncol 2003;25:864-867.
102. Liu CY, Jain V, Shields AF, Heilbrun LK. Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer. J Vasc Interv Radiol 2004;15:39-44.
103. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):401S-428S.
104. Schmittling ZC, McLafferty RB, Bohannon WT, et al. Characterization and probability of upper extremity deep venous thrombosis. Ann Vasc Surg 2004;18:552-557.
105. Frank DA, Meuse J, Hirsch D, et al. The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis 2000;10:271-275.
106. Hingorani A, Ascher E, Lorenson E et al. Upper extremity deep venous thrombosis and its impact on morbidity and mortality rates in a hospital-based population. J Vasc Surg 1997;26:853-860.
107. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000;47:763-766.
108. Kooij JD, van der Zant FM, van Beek EJ, Reekers JA. Pulmonary embolism in deep venous thrombosis of the upper extremity: more often in catheter-related thrombosis. Neth J Med 1997;50:238-242.
109. Ascher E, Salles-Cunha S, Hingorani A. Morbidity and mortality associated with internal jugular vein thromboses. Vasc Endovascular Surg 2005;39:335-339.
110. Bajzar L, Chan AK, Massicotte MP, Mitchell LG. Thrombosis in children with malignancy. Curr Opin Pediatr 2006;18:1-9.
111. Savage KJ, Wells PS, Schulz V, et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost 1999;82:1008-1010.
112. Karabay O, Yetkin U, Onol H. Upper extremity deep vein thrombosis: clinical and treatment characteristics. J Int Med Res 2004;32:429-435.
113. Herishanu Y, Misgav M, Kirgner I, et al. Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma 2004;45:1407-1411.
114. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (suppl 3):287S-310S.
115. Ascher E, Hingorani A, Tsemekhin B, et al. Lessons learned from a 6-year clinical experience with superior vena cava Greenfield filters. J Vasc Surg 2000;32:881-887.
116. Nadkarni S, Macdonald S, Cleveland TJ, Gaines PA. Placement of a retrievable Gunther Tulip filter in the superior vena cava for upper extremity deep venous thrombosis. Cardiovasc Intervent Radiol 2002;25:524-526.
117. Sabeti S, Schillinger M, Mlekusch W, et al. Treatment of subclavian-axillary vein thrombosis: long-term outcome of anticoagulation versus systemic thrombolysis. Thromb Res 2002;108:279-285.
118. Volkow P, Cornejo-Juarez P, Arizpe-Bravo AB, et al. Catheter-related septic thrombophlebitis of the great central veins successfully treated with low-dose streptokinase thrombolysis and antimicrobials. Thromb J 2005;3:11.